SequelSEC

ProMIS Neurosciences Inc. PMN

Pharmaceutical Preparations · CIK 0001374339 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$12.27M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

ProMIS Neurosciences Inc. (PMN) reported net income of -$11.73M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ProMIS Neurosciences Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ProMIS Neurosciences Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$12.27M-$8.64M-$10.77M-$11.75M-$10.18M-$7.46M-$6.00M-$4.43M-$2.71M-$3.68M
Net income-$11.73M-$8.24M-$10.67M-$11.58M-$10.12M-$7.35M-$238.21K$9.28M-$2.62M-$3.64M
Research & development$9.52M$6.97M$9.37M$9.80M$8.75M$5.46M$4.32M$2.56M$1.63M$2.12M
Weighted-average diluted sharesshares 9.14Mshares 6.53MUnavailableshares 48.83Mshares 1.39Mshares 1.39MUnavailableshares 30.07Mshares 19.77Mshares 19.53M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-1.28$-1.26Unavailable$-0.24$-7.26$-5.27Unavailable$0.31$-0.13$-0.19
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$2.74M$1.67M$1.40M$1.95M$1.43M$2.00M$1.68M$1.87M$1.09M$1.55M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

ProMIS Neurosciences Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$53.43M$63.81M$6.12M$15.40M$4.51M$8.36M$13.29M$21.54M$992.46K$2.50M
Total assets$56.69M$67.41M$9.18M$21.46M$9.51M$13.65M$18.91M$24.51M$1.41M$3.55M
Current assets$56.69M$65.61M$9.18M$21.46M$9.51M$13.65M$18.91M$24.51M$1.41M$3.55M
Total liabilities$7.29M$6.69M$10.44M$12.27M$9.89M$4.17M$2.42M$17.24M$3.69M$3.47M
Current liabilities$7.22M$6.61M$10.41M$12.21M$9.82M$4.06M$2.22M$2.64M$3.17M$2.65M
Total equity incl. NCI$49.40M$60.72M-$1.26M$9.19M-$382.58K$9.47M$16.49M$7.27M-$2.28M$77.10K
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.79M$1.72M$2.54M$4.21M$2.78M$1.20M$1.74M$1.58M$2.02M$1.40M

Cash flow

ProMIS Neurosciences Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$10.39M-$12.38M-$9.28M-$10.06M-$3.85M-$4.93M-$8.72M-$6.67M-$1.50M-$10.29M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$0$70.08M-$1UnavailableUnavailableUnavailable$470.00K$27.22M$0$190.27K
Net change in cash-$10.39M$57.70M-$9.28M$10.89M-$3.85M-$4.93M-$8.25M$20.54M-$1.50M-$10.10M
Stock-based compensation$408.89K$189.42K$203.17K$197.15K$212.02K$245.30K$623.19K$121.04K$18.00K$63.58K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

ProMIS Neurosciences Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio7.85x9.92x0.88x1.76x0.97x3.36x8.52x9.30x0.44x1.34x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PMN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-25View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.